How does the US price compare with other countries?
A public comment to the FDA showed the US list price of $234,900 far exceeded Japan's $93,600 and UK prices — and Medicare cannot negotiate tafamidis because researchers classify it as a "sole orphan" drug exempt under the IRA.
A public comment submitted to the FDA in a patent term restoration proceeding for Vyndamax argued that the US list price of $234,900 was markedly higher than in Japan, at $93,600, and in the United Kingdom. The same comment noted Pfizer's 2023 annual report disclosed $3.3 billion from the tafamidis family and urged the FDA to deny a patent term extension so generic competition could arrive sooner. Such price gaps are frequently cited in arguments that US patients and taxpayers subsidise lower prices abroad. Medicare cannot currently negotiate tafamidis's price either: it is not on the 2028 selected-drug list, and researchers have identified it as a "sole orphan" drug exempt from negotiation under the Inflation Reduction Act.